EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

31. What regulatory and commercial changes should a GLP-1 clinic monitor?

Dose Diligence research deskSection 01 · Page 31 of 34Last updated 17 Nov 2026

Monitor the events that can change your actual arrangement: product eligibility, facility permissions, safety information, programme terms and performing entities. Do not rely on a generic monthly news digest as the only control.

Suggested monitoring register:

TriggerAccountable reviewerRequired output
Shortage or compounding-policy changeCounsel and medical directorUpdated route assessment
Court orderCounselApplicability to the specific arrangement
Licence, inspection or recall developmentCompliance and qualityHold, investigation or documented disposition
Product label or presentation changeClinical and pharmacy leadsUpdated handling and prescribing workflow
Price or eligibility changeFinance and operationsRevised patient communications and model
Dispensing-partner changeProcurement and technologyEntity review and integration validation
Promotional claim changeCompliance and marketingApproved patient-facing language

FDA’s telehealth promotion guidance warns against misleading claims suggesting compounded products are approved or equivalent to approved products. Review the clinic’s own landing pages and scripts, not just the pharmacy’s materials. (fda.gov)

Use industry discussion to identify questions, not settle them. The compounding-industry perspective featured in the July 22, 2026 Everything GLP-1 podcast emphasizes patient-specific access; regulatory and quality questions still require primary-source assessment. (shows.acast.com)

Explore the table row by row

A working view of the research

Shortage or compounding-policy change

Accountable reviewer
Counsel and medical director
Required output
Updated route assessment

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs
  2. shows.acast.com · Source 2 ↗https://shows.acast.com/everything-glp-1/episodes/scott-brunner-inside-the-regulatory-battle-shaping-compounde
Section sources →